엡타플라틴

개요SKI-2053R was launched in Korea for the treatment of patients with advanced gastric adenocarcinoma. It is a third generation platinum complex alkylating agent with less nephrotoxicity than cisplatin. In in vitro experiments, SKI-2053R was highly active against various cell lines including cisplatinresistant tumor cell lines. In mice implanted with L1210 cells, SKI-2053R showed activity comparable or superior to cisplatin or carboplatin. In mice implanted s.c. with human tumor xenograft KATO III (stomach adenocarcinoma), SKI-2053R achieved growth-inhibition rates comparable with those of cisplatin. General pharmacological studies in animals did not display any severe adverse effects on the different systems at antitumour doses. Pharmacokinetic studies after a single iv administration in rats demonstrated that the compound was extensively and rapidly distributed into all tissues except the CNS. In patients with unresectable or metastatic gastric adenocarcinoma, SKI-2053R was active without significant hematological toxicity. Phase III trials with SKI-2053R are currently ongoing for the treatment of various other cancers including lung, head and neck.

용도A coordination compound for treatment of cervix cancer.